Company Overview and News

42
JD.com: Ridiculous Sell-Off Creates A Strong Buying Opportunity

2018-06-21 seekingalpha
JD.com and Google announced a comprehensive partnership following an equity injection exercise with cash from the latter.
JD CCGDF GOOGL WMT

0
SouthGobi announces appointment of Chief Executive Officer, Chief Financial Officer and Chief Operation Officer

2018-06-01 globenewswire
VANCOUVER, British Columbia, June 01, 2018 (GLOBE NEWSWIRE) -- SouthGobi Resources Ltd. (TSX:SGQ) (HK:1878) (“SouthGobi” or the “Company”) is pleased to announce the appointment, effective today, of Mr. Shougao Wang as Chief Executive Officer, Mr. Weiguo Zhang as Chief Financial Officer, and Mr. Aiming Guo as Chief Operating Officer.
CCGDF SGQ SGQRF

29
Professor Dingbo Xu Joins JD.com’s Board of Directors

2018-05-22 globenewswire
BEIJING, May 22, 2018 (GLOBE NEWSWIRE) -- JD.com Inc. (NASDAQ:JD), China’s leading technology-driven e-commerce company, today announced that Professor Dingbo Xu, a renowned accounting professor and associate dean at China Europe International Business School (CEIBS), has been elected to serve on the audit committee of JD.com’s board of directors and as the chairperson of the board’s nominating and corporate governance committee, effective immediately.
JD CCGDF

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...